Swedish Orphan Biovitrum AB

About Us

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

Contacts

Visiting address

Norra Stationsgatan 93A, Sweden

+46 8 697 20 00
info@sobi.com

Gerard Tobin

Head of Investor Relations

gerard.tobin@sobi.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Sobi™ publishes 2018 Annual and Sustainability Report

Thu, Apr 18, 2019 10:00 CET

Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company’s 2018 Annual and Sustainability Report. The integrated report summarises our business and strategy, financial performance and work on sustainability. “2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see

Sobi publishes the report for the fourth quarter and full-year 2018

Wed, Feb 20, 2019 08:00 CET

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the fourth quarter and full-year 2018. Total revenues grew 37 per cent compared with Q4 2017 (29 per cent at constant exchange rates (CER)) and amounted to SEK 2,571 M. EBITA was SEK 916 M, an increase of 48 per cent for the quarter, and gross margin amounted to 74 per cent. Highlights · Total revenues of SEK 2,571 M (1,875) in Q4 and SEK 9,139 M (6,511) for the full year · 37 per cent sales growth in Q4 compared with Q4 2017 (29 per cent at (CER)) · EBITA1increased 48 per cent

Sobi™ completes acquisition of Synagis® US rights from AstraZeneca and exercises authorisation to issue shares

Thu, Jan 24, 2019 08:00 CET

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018. Synagis is a medicine for the prevention of serious lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in high-risk infants and is the only approved preventative medicine for the condition. MEDI8897 is a follow-on

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth

Tue, Nov 13, 2018 08:00 CET

Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]

There are no items matching the current filter

There are no more items matching the current filter

Share